Guenter R. Janhofer, M.D., Ph.D.

Chief Medical Officer

Dr. Guenter R. Janhofer, M.D., Ph.D., has served as Quince’s Chief Medical Officer since October 2023. Previously, he was Chief Medical Officer of EryDel, S.p.A. since February 2018 prior to its acquisition by Quince in October 2023. With more than 30 years in the healthcare industry in roles of increasing complexity and scope, Dr. Janhofer’s clinical and regulatory leadership spans the management of more than 50 Phase 3 clinical trials and includes numerous FDA and global compound approvals – several of which were blockbuster drugs with commercial success that reached more than $1 billion in global sales each.

Previously, Dr. Janhofer served as the Head of Development and then Chief Medical Officer at BTG, a British healthcare company (acquired by Boston Scientific for $3.5 billion) specializing in interventional medicine across a broad spectrum of disease areas, including interventional oncology, pulmonology, and vascular diseases, and comprising drugs, biologics, and drug/device combinations. At BTG, he was responsible for the successful completion of the clinical development program of several compounds and subsequent regulatory approval by the FDA, such as Varisolve, a combination product for the treatment of varicose veins; Voraxase, a first in class treatment of Methotrexate overdose in oncology; and Ekos, a device treatment for acute and subacute treatment of pulmonary embolism, among others.

Prior to his tenure at BTG, Dr. Janhofer had a career at Merck, Inc. that included roles as Medical Director at the company’s European subsidiaries, as well as Vice President for Global Medical and Scientific Affairs at Merck’s U.S. headquarters. At Merck, he contributed to the clinical development and regulatory approval of numerous compounds, including PROSCAR, FOSAMAX, COZAAR/HYZAAR, S1NGULAIR, VIOXX, ARCOXIA, CANCIDAS, among others.

Dr. Janhofer holds several degrees, including an M.D. from the University of Hamburg, Germany, in addition to a Ph.D. in Climatology from the University of Bochum, Germany, and a post doctorate degree (Habilitation) in Epidemiology from the University of Technology of Berlin.

View Our Leadership